NasdaqGS:ACAD

Stock Analysis Report

Executive Summary

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders.

Snowflake

Fundamentals

Excellent balance sheet with high growth potential.

Share Price & News

How has ACADIA Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

4.7%

ACAD

0.8%

US Biotechs

1.0%

US Market


1 Year Return

90.4%

ACAD

-8.3%

US Biotechs

6.7%

US Market

Return vs Industry: ACAD exceeded the US Biotechs industry which returned -8.3% over the past year.

Return vs Market: ACAD exceeded the US Market which returned 6.7% over the past year.


Share holder returns

ACADIndustryMarket
7 Day4.7%0.8%1.0%
30 Day0.2%-3.9%-1.8%
90 Day54.2%-3.5%-1.8%
1 Year90.4%90.4%-7.5%-8.3%9.1%6.7%
3 Year66.6%66.6%13.6%9.6%46.1%36.6%
5 Year52.4%52.4%3.3%-1.7%66.9%48.6%

Price Volatility Vs. Market

How volatile is ACADIA Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is ACADIA Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

>50%

Discount to future cash flow value


Intrinsic Value Based on Future Cash Flows

Undervalued: ACAD ($40.52) is trading below our estimate of fair value ($167.58)

Significantly Undervalued: ACAD is trading below fair value by more than 20%.


Price Based on Earnings

PE vs Industry: ACAD is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: ACAD is unprofitable, so we can't compare its PE Ratio to the US market.


Price Based on Expected Growth

Low PEG Ratio: Insufficient data to calculate ACAD's PEG Ratio to determine if it is good value.


Price Based on Value of Assets

PB vs Industry: ACAD is overvalued based on its PB Ratio (15.1x) compared to the US Biotechs industry average (2.5x).


Next Steps

Future Growth

How is ACADIA Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 13 analysts?

75.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Earnings vs Savings Rate: ACAD is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.7%).

Earnings vs Market: ACAD is forecast to become profitable over the next 3 year, which is considered above average market growth.

High Growth Earnings: ACAD's loss is forecast to worsen by 0% next year.

Revenue vs Market: ACAD's revenue (46.2% per year) is forecast to grow faster than the US market (7.3% per year).

High Growth Revenue: ACAD's revenue (46.2% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Estimates


Future Return on Equity

High Future ROE: ACAD is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has ACADIA Pharmaceuticals performed over the past 5 years?

-20.7%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: ACAD is unprofitable, and losses have increased over the past 5 years at a rate of -20.7% per year.

Accelerating Growth: Unable to compare ACAD's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ACAD is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (78.4%).


Return on Equity

High ROE: ACAD has a negative Return on Equity (-68.88%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: ACAD is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: ACAD is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is ACADIA Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: ACAD's short term assets ($436.9M) exceeds its short term liabilities ($63.8M)

Long Term Liabilities: ACAD's short term assets (436.9M) exceeds its long term liabilities (8.2M)


Debt to Equity History and Analysis

Debt Level: ACAD is debt free.

Reducing Debt: ACAD has not had any debt for past 5 years.


Balance Sheet

Inventory Level: ACAD has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if ACAD's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ACAD has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if ACAD has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is ACADIA Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.8%industryaverage1.0%forecastin3Years0%

Current dividend yield vs market & industry


Dividend Yield and Payments Analysis

Notable Dividend: Unable to evaluate ACAD's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate ACAD's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if ACAD's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ACAD's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ACAD's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of ACADIA Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

1.2yrs

Average management tenure


CEO

Steve Davis (58yo)

4.1yrs

Tenure

US$6,508,032

Compensation

Mr. Stephen R. Davis, also known as Steve, J.D., serves as the Director at Heron Therapeutics Inc. since October 2019. He has been the Chief Executive Officer of ACADIA Pharmaceuticals, Inc. since Septembe ...


CEO Compensation Analysis

Compensation vs. Market: Steve's total compensation ($USD6.51M) is about average for companies of similar size in the US market ($USD6.81M).

Compensation vs Earnings: Steve's compensation has been consistent with company performance over the past year.


Management Age and Tenure

1.2yrs

Average Tenure

57yo

Average Age

Experienced Management: ACAD's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.


Board Age and Tenure

4.0yrs

Average Tenure

62yo

Average Age

Experienced Board: ACAD's board of directors are considered experienced (4 years average tenure).


Insider Trading

Insider Buying: ACAD insiders have only sold shares in the past 3 months.


Recent Insider Transactions

BuyUS$62,500,00020 Sep 19
Baker Bros. Advisors LP
EntityCompany
Shares1,562,500
Max PriceUS$40.00
SellUS$191,28111 Sep 19
Eric Miller
EntityIndividual
Role
Chief Accounting Officer
Controller & Principal Accounting Officer
Shares4,645
Max PriceUS$41.18
BuyUS$199,999,98504 Dec 18
Baker Bros. Advisors LP
EntityCompany
Shares11,764,705
Max PriceUS$17.00

Ownership Breakdown


Management Team

  • Steve Davis (58yo)

    CEO & Director

    • Tenure: 4.1yrs
    • Compensation: US$6.51m
  • Eliseo Salinas (63yo)

    Senior VP

    • Tenure: 1.1yrs
  • Elena Ridloff (39yo)

    Executive VP & CFO

    • Tenure: 1yrs
  • Serge Stankovic (62yo)

    President

    • Tenure: 0.9yrs
    • Compensation: US$5.68m
  • Ryan Brown

    Chief Compliance Officer & VP

    • Tenure: 4.2yrs
  • Bob Mischler

    Senior Vice President of Strategy & Technology Operations

    • Tenure: 0yrs
  • Mark Johnson

    Vice President of Investor Relations

    • Tenure: 0yrs
  • Michael Yang (57yo)

    Executive VP & Chief Commercial Officer

    • Tenure: 2.6yrs
    • Compensation: US$3.18m
  • Austin Kim (55yo)

    Executive VP

    • Tenure: 1.3yrs
    • Compensation: US$2.13m
  • Eric Miller (40yo)

    Controller & Principal Accounting Officer

    • Tenure: 0.9yrs

Board Members

  • Laura Brege (61yo)

    Independent Director

    • Tenure: 11.4yrs
    • Compensation: US$793.63k
  • Steve Davis (58yo)

    CEO & Director

    • Tenure: 4.1yrs
    • Compensation: US$6.51m
  • Jim Baker (52yo)

    Independent Director

    • Tenure: 3.8yrs
    • Compensation: US$231.28k
  • Paul Anderson (80yo)

    Member of the Scientific and Clinical Advisory Board

    • Tenure: 0yrs
  • Ed Harrigan (66yo)

    Independent Director

    • Tenure: 3.9yrs
    • Compensation: US$394.55k
  • Dan Soland (63yo)

    Independent Director

    • Tenure: 4.6yrs
    • Compensation: US$412.57k
  • Arvid Carlsson (96yo)

    Member of the Scientific and Clinical Advisory Board

    • Tenure: 0yrs
  • Carol Tamminga

    Member of the Scientific and Clinical Advisory Board

    • Tenure: 0yrs
  • Herb Meltzer

    Member of the Scientific and Clinical Advisory Board

    • Tenure: 0yrs
  • Stephen Biggar (48yo)

    Independent Chairman of the Board

    • Tenure: 3.3yrs
    • Compensation: US$276.28k

Company Information

ACADIA Pharmaceuticals Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: ACADIA Pharmaceuticals Inc.
  • Ticker: ACAD
  • Exchange: NasdaqGS
  • Founded: 1993
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$6.108b
  • Shares outstanding: 150.74m
  • Website: https://www.acadia-pharm.com

Number of Employees


Location

  • ACADIA Pharmaceuticals Inc.
  • 3611 Valley Centre Drive
  • Suite 300
  • San Diego
  • California
  • 92130
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ACADNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDMay 2004
DR6DB (Deutsche Boerse AG)YesCommon StockDEEURMay 2004

Biography

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The  ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/14 01:49
End of Day Share Price2019/10/11 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

© 2018 SIMPLY WALL STREET PTY LTD, COMMUNITY DESIGN 2845206, US DESIGN PATENT #29/544/281, EUROPEAN DESIGN REGISTRATION #2845206, STANDARD & POOR’S FINANCIAL SERVICES LLC. ALL RIGHTS RESERVED.

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Copyright © 2018, Standard & Poor’s Financial Services LLC. Reproduction of S&P Capital IQ in any form is prohibited except with the prior written permission of S&P. S&P does not guarantee the accuracy, adequacy, completeness or availability of any information and is not responsible for any errors or omissions, regardless of the cause or for the results obtained from the use of such information. S&P DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. In no event shall S&P be liable for any direct, indirect, special or consequential damages, costs, expenses, legal fees, or losses (including lost income or lost profit and opportunity costs) in connection with subscriber’s or others’ use of S&P Capital IQ. (2018)